Shire Pharmaceuticals Braced for US Study into Heart Risks of Attention Deficit Drug

The Guardian -- Pharmaceutical group Shire is braced for a report from US regulators on the safety of drugs used to treat attention-deficit hyperactivity disorder (ADHD) which could affect almost a third of its annual sales of $3bn (£1.9bn).